LIQUIDITY AND FINANCIAL CONDITION (Details) - USD ($)			1 Months Ended					3 Months Ended		6 Months Ended
	Jun. 30, 2024	Aug. 31, 2021	Jul. 31, 2024	Jun. 30, 2024	May 31, 2023	Sep. 30, 2022	Aug. 31, 2021	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Jun. 26, 2023
LIQUIDITY AND FINANCIAL CONDITION
Cash and cash equivalents	$ 7,800,464			$ 7,800,464				$ 7,800,464		$ 7,800,464		$ 15,111,450
Proceeds from issuance of common stock, net										36,902	$ 619,974
Amount of notice received		$ 13,100,000
Funds received from CPRIT grant										9,700,000
Grant income receivable	200,000			200,000				200,000		200,000
Revenue recognized								$ 1,169,236	$ 762,658	$ 2,413,297	$ 1,996,995
Common Stock
LIQUIDITY AND FINANCIAL CONDITION
Number of shares issued (in shares)								8,178		8,178	212,761
SBIR grant
LIQUIDITY AND FINANCIAL CONDITION
Other receivables	200,000			200,000				$ 200,000		$ 200,000
Funds received from grant										600,000
Grant income received					$ 2,000,000.0
Grant income receivable	200,000			$ 200,000				200,000		200,000
Revenue recognized								200,000		400,000
National Institutes of Health National -Cancer Institute Grant
LIQUIDITY AND FINANCIAL CONDITION
Grant Assistance Term				2 years
Grant income received				$ 2,000,000.0
Grant income
LIQUIDITY AND FINANCIAL CONDITION
Funds received from grant	1,900,000
Revenue from CPRIT								700,000		1,500,000
Revenue recognized								1,169,236	$ 762,658	2,413,297	$ 1,996,995
FDA grant
LIQUIDITY AND FINANCIAL CONDITION
Funds received from grant										1,000,000.0
Grant income received						$ 2,000,000.0
Grant income receivable	$ 200,000			$ 200,000				200,000		200,000
Revenue recognized								$ 200,000		$ 500,000
Subsequent event
LIQUIDITY AND FINANCIAL CONDITION
Funds received from grant			$ 200,000
Funds received from CPRIT grant			2,800,000
Subsequent event | SBIR grant
LIQUIDITY AND FINANCIAL CONDITION
Funds received from grant			200,000
Subsequent event | FDA grant
LIQUIDITY AND FINANCIAL CONDITION
Funds received from grant			$ 200,000
ATM Agreement
LIQUIDITY AND FINANCIAL CONDITION
Aggregate offering price		$ 75,000,000.0					$ 75,000,000.0
ATM Agreement | Sales Agents
LIQUIDITY AND FINANCIAL CONDITION
Commission rate							3.00%
Number of shares issued (in shares)								8,178		8,178
Proceeds from issuance of common stock, net								$ 40,000.00		$ 40,000.00
Cell Ready Purchase Agreement
LIQUIDITY AND FINANCIAL CONDITION
Consideration for purchased assets													$ 19,000,000.0